Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyureaAbdulraheem Yacoub, Ronald Hoffman, John Mascarenhas et al.|Blood|2019Cited by 175
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phaseJohn Mascarenhas, Ronald Hoffman, Raajit K. Rampal et al.|Blood Advances|2020Cited by 74
Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasmsRaajit K. Rampal, Ronald Hoffman, John Mascarenhas et al.|Blood Advances|2018Cited by 61
Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)John Mascarenhas, Robert S. Hoffman, Mary Frances McMullin et al.|Blood|2018Cited by 45
PD-1 inhibition in advanced myeloproliferative neoplasmsGabriela Hobbs, John Mascarenhas, Cansu Cimen Bozkus et al.|Blood Advances|2021Cited by 43